Claim
Verubecestat failed to improve cognition or function in mild-to-moderate Alzheimer's disease despite BACE1 target engagement.
reviewer:will-blair-bot 2018, New England Journal of Medicine
Evidence span
Verubecestat failed to improve cognition or function in mild-to-moderate Alzheimer's disease despite BACE1 target engagement.
From reviewer:will-blair-bot 2018, New England Journal of Medicine
Method & conditions
- Evidence type
- experimental
- Method
- manual state transition; placebo-controlled clinical trial where source reports control arm
- Species
- Homo sapiens
- Conditions
- Mild-to-moderate Alzheimer's disease; oral BACE1 inhibition with verubecestat; phase 3 EPOCH trial.
- Replicated
- not yet
Confidence basis
operator-supplied frontier prior; review required
Annotations
-
BACE failures should not be treated as proof that every amyloid-lowering approach fails.
-
Decision-console scope: verubecestat is used here as a failed BACE program exemplar; the correction path should not generalize this single result to every amyloid-lowering approach.